

File No. 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(1)

Government of India
Ministry of Chemical & Fertilizers
Department of Pharmaceuticals
National Pharmaceuticals Pricing Authority

3rd and 5th Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi-110001


Dated: 28th October ,2024

OFFICE MEMORANDUM

The undersigned is directed to refer to the Department of Revenue, Ministry of Finance Notification 30/2024 dated 23.07.2024 vide which Custom Duty on three (3) Anti-cancer medicines namely, Trastuzumab Deruxtecan, Osimertinib and Durvalumab was reduced to Nil. Further, Department of Revenue, Gol has reduced GST rates from 12% to 5% on these Anti-cancer drugs vide Notification no. 05/2024 dated 08.10.2024, which has come into force from 10.10.2024.

2. As per DPCO, 2013, Maximum Retail Price (MRP) of drugs/formulations is inclusive of taxes and duties, as applicable. Hence, any downward change in Duties and Taxes should be reflected in the MRP and benefit of Nil duty/ Reduction in duties/Taxes should be passed on to consumers.

3. In view of the above, all the manufacturers and marketing companies selling the above-mentioned drugs/formulations are required to revise the MRP of drugs/formulations on which Custom duty has been made Nil and GST has been reduced. Information about the revision is required to be submitted through Form-II/ Form V and the manufacturers shall issue a price list or supplementary price list to the dealers, State Drugs Controllers and the Government indicating changes.


(Rashmi Tahiliani)
Director (Pricing)

To,

All the manufacturers and marketing companies of drugs/formulations for compliance.

Copy to:

1. PSO to Secretary (Pharma), Government of India
2. Drug Controller General (India)
3. All the Drug Controllers / Food & Drug Administration of all the State / UT Governments.